NCT07611214RecruitingPhase 4
PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients With Lupus Nephritis
Aurinia Pharmaceuticals Inc.27 sites in 1 country150 target enrollmentStarted: April 22, 2026Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- Aurinia Pharmaceuticals Inc.
- Enrollment
- 150
- Locations
- 27
Study Overview
Brief Summary
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
Detailed Description
Patients with LN will be administered LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab. Additionally, patients will receive treatment with a mycophenolic acid analog (MPAA), specifically mycophenolate mofetil (MMF) or mycophenolic acid (MPA), and oral prednisone (or equivalent).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adults 18-75 years old
- •Diagnosed with biopsy-proven lupus nephritis (LN) according to the 2003 International Society of Nephrology (ISN) / Renal Pathology Society (RPS) (class III, class IV, class III/V or class IV/V)
- •Urine protein-to-creatine ratio (UPCR) ≥0.5 g/g and <5.0 g/g from a first morning void (FMV) urine sample
- •Estimated glomerular filtration rate (eGFR) of ≥45 mL/min/1.73 m2
- •Concomitant biologic:
- •Patients on the belimumab or anifrolumab treatment regimens are receiving belimumab or anifrolumab (as applicable) prior to Screening or will initiate belimumab or anifrolumab (as applicable) on or before Day
- •Patients on the obinutuzumab treatment regimen must have received at least 2 administrations of obinutuzumab prior to Screening.
- •Willing to take mycophenolic acid analog (MPAA), either by continuing current MPAA therapy or by initiating it on or before Day 1
- •Willing to take corticosteroids, either by continuing current corticosteroids (prednisone [or equivalent]) or by initiating on or before Day 1
Exclusion Criteria
- •Any B cell targeted therapy except for the concomitant biologics (belimumab and obinutuzumab) within 1 year prior to Screening unless demonstration of B cell count within the normal range
- •Cyclophosphamide or any calcineurin inhibitor other than voclosporin (eg, cyclosporine and tacrolimus) within 3 months prior to Screening
- •Any other immunosuppressive therapy except for the concomitant drugs (anifrolumab, MPAAs and oral prednisone [or equivalent]) and immunosuppressive agents used to treat a patient's underlying systemic lupus erythematosus (SLE), including, but not limited to, the examples below, within 30 days or 5 half-lives, whichever is longer, prior to Screening:
- •Anti-tumor necrosis factor (TNF) therapy (eg, adalimumab, etanercept, infliximab)
- •Anti-interleukin therapy (eg, risankizumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tocilizumab, dupilumab)
- •T cell costimulation modulator (eg, abatacept)
- •Intravenous immunoglobulin (IVIg)
- •Janus kinase (JAK) inhibitors (eg, upadacitinib)
- •Pregnant, breastfeeding or intending to become pregnant during the Study
Arms & Interventions
LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab
Experimental
Patients will also receive concomitant mycophenolic acid analog and corticosteroids.
Intervention: mycophenolic acid analog (MPAA) (Drug)
LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab
Experimental
Patients will also receive concomitant mycophenolic acid analog and corticosteroids.
Intervention: corticosteroid (Drug)
LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab
Experimental
Patients will also receive concomitant mycophenolic acid analog and corticosteroids.
Intervention: belimumab, obinutuzumab or anifrolumab (Biological)
Investigators
Study Sites (27)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal CancerNCT07405736Sun Yat-sen University124
Recruiting
Phase 3
Randomized, multicenter, double-blind, Phase 3 study investigating the safety and efficacy of dostarlimab plus belrestotug compared with pembrolizumab plus placebo in participants with previously untreated, unresectable, locally advanced or metastatic Non-small-cell lung cancerCTRI/2024/10/075244GlaxoSmithKline1,000
Recruiting
Phase 2
Study to evaluate long-term safety and efficacy of Lunsekimig in participants with moderate to severe asthmaCTRI/2025/03/081865Sanofi Healthcare India Pvt Limited467
Not yet recruiting
Phase 4
Lupin Dental smile designing India StudyCTRI/2025/10/095662Lupin Dental45
Recruiting
Phase 3
Study to evaluate efficacy and safety of Human normal immunoglobulin given in veins in patients with Immune thrombocytopenia (Low levels of the cells that help blood clot)CTRI/2025/08/093411Bharat Serums and Vaccines Ltd30